PPAR𝜸 and MEK Interactions in Cancer

Table 1

Combination therapy with PPAR ligands.

Cancer type	PPAR ligand	Combination	Inhibitor type	Reference
In vitro
CML	TZD18	Imatinib	Abl, other RPTKs	[122]
NSCLC A549	Rosiglitazone	Gefitinib	EGFR/Her1	[144]
Breast MCF7	Troglitazone	Herceptin	Mab-Her2/ErbB2	[145]
In vivo (human xenografts or chemically-induced tumors in rodents)
NSCLC A549	Pioglitazone	PX-866 Gefitinib	PI3K-p110 Her1/EGFR	[149]
Breast (by NMU)	Rosiglitazone	Tamoxifen	SERM	[150]
Thyroid ATC	RS5444	Paclitaxel	Chemotherapeutic	[120]
Clinical studies
Melanoma Sarcoma	Pioglitazone	Rofecoxib Trofosfamide	COX2 Chemotherapeutic	[151–153]
Advanced Solid tumors	LY293111	Irinotecan Gemcitabine	Chemotherapeutic Chemotherapeutic	[154–156]
Glioblastoma Anaplastic Glioma	Pioglitazone	Rofecoxib Capecitabine Temozolomide	COX2 Chemotherapeutic Chemotherapeutic	[157]